FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rémy Morgentin

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Transplantation, Heterologous

Living Beings

Co-author Network

Publications

TOP 3
Patrick A Plé; Sue Ashton; Laurent F A Hennequin; Frédéric Jung; Romuald Laine; Christine Lambert-Van Der Brempt; Rémy Morgentin; Georges Pasquet; Sian Taylor
Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.
M Raymond V Finlay; David G Acton; David M Andrews; Andrew J Barker; Michael Dennis; Eric Fisher; Mark A Graham; Clive P Green; David W Heaton; Galith Karoutchi; Sarah A Loddick; Rémy Morgentin; Andrew Roberts; Julie A Tucker; Hazel M Weir
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Laurent F A Hennequin; Jack Allen; Jason Breed; Jon O Curwen; Michael Fennell; Tim P Green; Christine Lambert-Van Der Brempt; Rémy Morgentin; Richard A Norman; Annie Olivier; Ludovic R Otterbein; Patrick A Plé; Nicolas Warin; Gerard Costello
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rémy Morgentin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Patrick A Plé; Sue Ashton; Laurent F A Hennequin; Frédéric Jung; Romuald Laine; Christine Lambert-Van Der Brempt; Rémy Morgentin; Georges Pasquet; Sian Taylor
Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.
Bioorganic & medicinal chemistry letters 2012;22(9):3050-5.
2008: M Raymond V Finlay; David G Acton; David M Andrews; Andrew J Barker; Michael Dennis; Eric Fisher; Mark A Graham; Clive P Green; David W Heaton; Galith Karoutchi; Sarah A Loddick; Rémy Morgentin; Andrew Roberts; Julie A Tucker; Hazel M Weir
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Bioorganic & medicinal chemistry letters 2008;18(15):4442-6.
2006: Laurent F A Hennequin; Jack Allen; Jason Breed; Jon O Curwen; Michael Fennell; Tim P Green; Christine Lambert-Van Der Brempt; Rémy Morgentin; Richard A Norman; Annie Olivier; Ludovic R Otterbein; Patrick A Plé; Nicolas Warin; Gerard Costello
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Journal of medicinal chemistry 2006;49(22):6465-88.
2006: Peter Ballard; Robert H Bradbury; Craig S Harris; Laurent F A Hennequin; Mark Hickinson; Paul D Johnson; Jason G Kettle; Teresa Klinowska; Andrew G Leach; Rémy Morgentin; Martin Pass; Donald J Ogilvie; Annie Olivier; Nicolas Warin; Emma J Williams
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Bioorganic & medicinal chemistry letters 2006;16(6):1633-7.
2005: Bernard Barlaam; Michael Fennell; Hervé Germain; Tim Green; Laurent F A Hennequin; Rémy Morgentin; Annie Olivier; Patrick A Plé; Michel Vautier; Gerard Costello
New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors.
Bioorganic & medicinal chemistry letters 2005;15(24):5446-9.
2005: Peter Ballard; Robert H Bradbury; Laurent F A Hennequin; D Mark Hickinson; Paul D Johnson; Jason G Kettle; Teresa Klinowska; Rémy Morgentin; Donald J Ogilvie; Annie Olivier
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorganic & medicinal chemistry letters 2005;15(19):4226-9.